Arvinas Estrogen Receptor
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Arvinas Estrogen Receptor sits in the upper half of US sponsors by registered trial count (#4,887 of 15,751 sponsors by registered trial count).
Arvinas Estrogen Receptor: 2 sponsored US clinical trials, none currently recruiting.
Arvinas Estrogen Receptor sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 1 trials.
Mid-pack sponsor footprint
Arvinas Estrogen Receptor is in the upper half of sponsors by trial count (#4,887 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT04072952
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
NCT05501769
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
How the Arvinas Estrogen Receptor early-phase archive is shaped
2 indexed studies, none listed as recruiting (0% open); 1 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.